Neurocil (Levomepromazine Maleate)

Levomepromazine acts primarily as a dopamine D2 receptor antagonist, reducing dopaminergic activity that contributes to psychosis. It also blocks histamine H1, muscarinic, and alpha‑adrenergic receptors, providing sedation, anti‑emetic effects, and blood‑pressure lowering. The combined receptor blockade modulates several central nervous system pathways, producing its therapeutic actions.

The dosage of Neurocil is individualized by the prescribing clinician based on the specific indication, patient age, weight, renal and hepatic function, and response to therapy. Physicians determine the appropriate starting dose and titration schedule, and patients should follow the prescribed regimen without alteration.

Safety data for levomepromazine in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss risks and alternatives with their healthcare provider.

To request Neurocil, visit the product page on gnhindia.com, enter the required quantity, and submit the enquiry form. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Neurocil belongs to the typical antipsychotic class (phenothiazines) and differs from atypical agents by having stronger dopamine D2 blockade and a higher propensity for extrapyramidal symptoms. It offers additional antihistaminic and anti‑emetic properties, making it useful for nausea control and palliative sedation, whereas many atypicals focus more on metabolic side‑effect profiles.

Neurocil should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keeping the product in a dry, temperature‑controlled environment helps maintain its stability and potency throughout its shelf life.

Neurocil is supplied as an oral formulation and is taken by mouth with or without food, as directed by the prescriber. The tablet should be swallowed whole with water; crushing or chewing may affect absorption and should be avoided unless specifically instructed by a healthcare professional.

The most serious risks include neuroleptic malignant syndrome, a rare but life‑threatening reaction characterized by fever, muscle rigidity, and autonomic instability; severe cardiac arrhythmias such as torsades de pointes; agranulocytosis leading to infection risk; and profound hypotension or syncope. Immediate medical attention is required if any of these occur.

Neurocil is contraindicated in patients with known hypersensitivity to levomepromazine or other phenothiazines, those with a history of neuroleptic malignant syndrome, and individuals with severe cardiovascular disease where orthostatic hypotension could be hazardous. Caution is also advised for patients with uncontrolled epilepsy, severe liver or kidney impairment, and for those taking interacting medications listed under major interactions.